During this time period, the interest in the use of bevacizumab in HER2-positive breast cancer was also high due to studies demonstrating association between HER2 amplification and increased vascular endothelial growth factor (VEGF) in breast cancer [3–5]. This evidence concerns the gene ERBB2 and breast cancer.